

# Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

## CD3 Monoclonal Antibody (OKT3), APC, eBioscience

RRID:AB\_1907372

Type: Antibody

### Proper Citation

(Thermo Fisher Scientific Cat# 17-0037-42, RRID:AB\_1907372)

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_1907372](http://antibodyregistry.org/AB_1907372)

**Proper Citation:** (Thermo Fisher Scientific Cat# 17-0037-42, RRID:AB\_1907372)

**Target Antigen:** CD3

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: Flow  
Consolidation on 1/2020: AB\_1907372, AB\_10485931

**Antibody Name:** CD3 Monoclonal Antibody (OKT3), APC, eBioscience

**Description:** This monoclonal targets CD3

**Target Organism:** human

**Clone ID:** Clone OKT3

**Antibody ID:** AB\_1907372

**Vendor:** Thermo Fisher Scientific

**Catalog Number:** 17-0037-42

**Record Creation Time:** 20251213T073655+0000

**Record Last Update:** 20260225T230832+0000

### Ratings and Alerts

No rating or validation information has been found for CD3 Monoclonal Antibody (OKT3), APC, eBioscience.

No alerts have been found for CD3 Monoclonal Antibody (OKT3), APC, eBioscience.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Cook DR, et al. (2025) Checkpoint antibody receptor modified ARMed CAR T circumvents the suppressive immunome in GBM. *Frontiers in immunology*, 16, 1579925.

Rokan A, et al. (2025) Evolution of a melanoma that escapes allogeneic rejection. *Cell reports*, 44(9), 116288.

Deng S, et al. (2024) ITPRIPL1 binds CD3? to impede T cell activation and enable tumor immune evasion. *Cell*, 187(9), 2305.

Yu T, et al. (2023) TRIM11 attenuates Treg cell differentiation by p62-selective autophagic degradation of AIM2. *Cell reports*, 42(10), 113231.

Celis-Gutierrez J, et al. (2019) Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. *Cell reports*, 27(11), 3315.